Ascentage Pharma's EBIT loss and liabilities compared to cas...
Ascentage Pharma's EBIT loss and liabilities compared to cash and near-term receivables raise debt usage concerns. The company's stock position appears risky after burning through CN¥814m of cash in a year.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000147204c3c72490.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment